SGLT2 inhibitors in T2D and associated comorbidities - Differentiating within the class

Guntram Schernthaner, Heinz Drexel, Evgeny Moshkovich, Birute Zilaitiene, Emil Martinka, Leszek Czupryniak, T. Várkonyi, Andrej Janež, Kristine Ducena, Katarina Lalić, Tsvetalina Tankova, Martin Prázný, Lea Smirčić Duvnjak, Olga Sukhareva, Harald Sourij

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME. Expert opinion: To debate newly available CVOT data and to put them into context, we convened as a group of medical experts from the Central and Eastern European Region. Here we describe our discussions, focusing on the conclusions we can draw from EMPA-REG OUTCOME and other SGLT2 inhibitor CVOTs, including when considered alongside real-world evidence. Conclusion: CVOTs investigating SGLT2 inhibitors have suggested benefits beyond glucose lowering that have been confirmed in real-world evidence studies.

Original languageEnglish
Article number64
JournalBMC Endocrine Disorders
Volume19
Issue number1
DOIs
Publication statusPublished - Jun 17 2019

Fingerprint

Type 2 Diabetes Mellitus
Comorbidity
Expert Testimony
Cardiovascular Diseases
Safety
Glucose
Mortality
Pharmaceutical Preparations
empagliflozin

Keywords

  • Canagliflozin
  • Cardiovascular disease
  • Dapagliflozin
  • Empagliflozin
  • SGLT2 inhibitor
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Schernthaner, G., Drexel, H., Moshkovich, E., Zilaitiene, B., Martinka, E., Czupryniak, L., ... Sourij, H. (2019). SGLT2 inhibitors in T2D and associated comorbidities - Differentiating within the class. BMC Endocrine Disorders, 19(1), [64]. https://doi.org/10.1186/s12902-019-0387-y

SGLT2 inhibitors in T2D and associated comorbidities - Differentiating within the class. / Schernthaner, Guntram; Drexel, Heinz; Moshkovich, Evgeny; Zilaitiene, Birute; Martinka, Emil; Czupryniak, Leszek; Várkonyi, T.; Janež, Andrej; Ducena, Kristine; Lalić, Katarina; Tankova, Tsvetalina; Prázný, Martin; Smirčić Duvnjak, Lea; Sukhareva, Olga; Sourij, Harald.

In: BMC Endocrine Disorders, Vol. 19, No. 1, 64, 17.06.2019.

Research output: Contribution to journalArticle

Schernthaner, G, Drexel, H, Moshkovich, E, Zilaitiene, B, Martinka, E, Czupryniak, L, Várkonyi, T, Janež, A, Ducena, K, Lalić, K, Tankova, T, Prázný, M, Smirčić Duvnjak, L, Sukhareva, O & Sourij, H 2019, 'SGLT2 inhibitors in T2D and associated comorbidities - Differentiating within the class', BMC Endocrine Disorders, vol. 19, no. 1, 64. https://doi.org/10.1186/s12902-019-0387-y
Schernthaner G, Drexel H, Moshkovich E, Zilaitiene B, Martinka E, Czupryniak L et al. SGLT2 inhibitors in T2D and associated comorbidities - Differentiating within the class. BMC Endocrine Disorders. 2019 Jun 17;19(1). 64. https://doi.org/10.1186/s12902-019-0387-y
Schernthaner, Guntram ; Drexel, Heinz ; Moshkovich, Evgeny ; Zilaitiene, Birute ; Martinka, Emil ; Czupryniak, Leszek ; Várkonyi, T. ; Janež, Andrej ; Ducena, Kristine ; Lalić, Katarina ; Tankova, Tsvetalina ; Prázný, Martin ; Smirčić Duvnjak, Lea ; Sukhareva, Olga ; Sourij, Harald. / SGLT2 inhibitors in T2D and associated comorbidities - Differentiating within the class. In: BMC Endocrine Disorders. 2019 ; Vol. 19, No. 1.
@article{2352b907a2904732b3a49c2dcfe0930e,
title = "SGLT2 inhibitors in T2D and associated comorbidities - Differentiating within the class",
abstract = "Background: For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME. Expert opinion: To debate newly available CVOT data and to put them into context, we convened as a group of medical experts from the Central and Eastern European Region. Here we describe our discussions, focusing on the conclusions we can draw from EMPA-REG OUTCOME and other SGLT2 inhibitor CVOTs, including when considered alongside real-world evidence. Conclusion: CVOTs investigating SGLT2 inhibitors have suggested benefits beyond glucose lowering that have been confirmed in real-world evidence studies.",
keywords = "Canagliflozin, Cardiovascular disease, Dapagliflozin, Empagliflozin, SGLT2 inhibitor, Type 2 diabetes",
author = "Guntram Schernthaner and Heinz Drexel and Evgeny Moshkovich and Birute Zilaitiene and Emil Martinka and Leszek Czupryniak and T. V{\'a}rkonyi and Andrej Janež and Kristine Ducena and Katarina Lalić and Tsvetalina Tankova and Martin Pr{\'a}zn{\'y} and {Smirčić Duvnjak}, Lea and Olga Sukhareva and Harald Sourij",
year = "2019",
month = "6",
day = "17",
doi = "10.1186/s12902-019-0387-y",
language = "English",
volume = "19",
journal = "BMC Endocrine Disorders",
issn = "1472-6823",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - SGLT2 inhibitors in T2D and associated comorbidities - Differentiating within the class

AU - Schernthaner, Guntram

AU - Drexel, Heinz

AU - Moshkovich, Evgeny

AU - Zilaitiene, Birute

AU - Martinka, Emil

AU - Czupryniak, Leszek

AU - Várkonyi, T.

AU - Janež, Andrej

AU - Ducena, Kristine

AU - Lalić, Katarina

AU - Tankova, Tsvetalina

AU - Prázný, Martin

AU - Smirčić Duvnjak, Lea

AU - Sukhareva, Olga

AU - Sourij, Harald

PY - 2019/6/17

Y1 - 2019/6/17

N2 - Background: For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME. Expert opinion: To debate newly available CVOT data and to put them into context, we convened as a group of medical experts from the Central and Eastern European Region. Here we describe our discussions, focusing on the conclusions we can draw from EMPA-REG OUTCOME and other SGLT2 inhibitor CVOTs, including when considered alongside real-world evidence. Conclusion: CVOTs investigating SGLT2 inhibitors have suggested benefits beyond glucose lowering that have been confirmed in real-world evidence studies.

AB - Background: For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME. Expert opinion: To debate newly available CVOT data and to put them into context, we convened as a group of medical experts from the Central and Eastern European Region. Here we describe our discussions, focusing on the conclusions we can draw from EMPA-REG OUTCOME and other SGLT2 inhibitor CVOTs, including when considered alongside real-world evidence. Conclusion: CVOTs investigating SGLT2 inhibitors have suggested benefits beyond glucose lowering that have been confirmed in real-world evidence studies.

KW - Canagliflozin

KW - Cardiovascular disease

KW - Dapagliflozin

KW - Empagliflozin

KW - SGLT2 inhibitor

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85067579055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067579055&partnerID=8YFLogxK

U2 - 10.1186/s12902-019-0387-y

DO - 10.1186/s12902-019-0387-y

M3 - Article

C2 - 31208401

AN - SCOPUS:85067579055

VL - 19

JO - BMC Endocrine Disorders

JF - BMC Endocrine Disorders

SN - 1472-6823

IS - 1

M1 - 64

ER -